Finance
EQT backs out of takeover bid for UK's Oxford Biomedica
Published by Global Banking & Finance Review®
Posted on February 25, 2026
1 min readLast updated: February 25, 2026
Quick Summary
On Feb 25, 2026, EQT said it will not proceed with a takeover of Oxford Biomedica, sending OXB shares down nearly 10%. Under Rule 2.8, EQT is restricted from making another approach unless conditions change.
EQT Walks Away From Takeover Bid for UK’s Oxford Biomedica plc
Decision Announced on Feb 25, 2026
EQT Ends Oxford Biomedica Takeover Talks
Feb 25 (Reuters) - Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica, sending the British cell and gene therapy manufacturer's shares down nearly 10%.
Byline and Attribution
(Reporting by Ankita Bora in Bengaluru; Editing by Shreya Biswas)
Key Takeaways
- •EQT decided not to proceed with a takeover of Oxford Biomedica.
- •The Rule 2.8 statement restricts EQT from making another offer for a period unless exceptions apply.
- •Oxford Biomedica shares fell nearly 10% on the news.
- •The PUSU deadline had been extended to Feb 25, 2026, before EQT withdrew.
- •No financial terms or reasons for withdrawal were disclosed.
Frequently Asked Questions about EQT backs out of takeover bid for UK's Oxford Biomedica
1What is the main topic?
EQT decided not to proceed with a takeover of Oxford Biomedica on Feb 25, 2026, which led to a near-10% drop in the biotech firm’s shares.
2Why did EQT withdraw its offer?
EQT issued a Rule 2.8 statement saying it does not intend to make an offer. The announcement did not disclose reasons or terms.
3What are the implications under UK takeover rules?
After a Rule 2.8 statement, EQT is generally restricted for six months from making another offer unless exceptions apply, such as a third-party bid or board consent.
